旅行疫苗市场 - 全球产业规模、份额、趋势、机会及预测（依成分、疾病、旅游类型、地区及竞争格局划分，2021-2031年）

全球旅行疫苗市场预计将从 2025 年的 68.1 亿美元成长到 2031 年的 115.6 亿美元，复合年增长率达到 9.22%。

旅行疫苗是旨在为前往特定地区的旅行者提供针对当地性行为感染的获得性免疫的生物製药。市场成长的主要驱动力是国际观光的强劲復苏以及各国政府严格的签证签发强制接种疫苗规定。全球可支配收入的成长进一步推动了这一扩张，促进了跨境旅行和商务旅行。联合国世界旅游组织的数据显示，到2024年，国际观光人数将恢復到疫情前水准的96%，这预示着全球流动性的强劲復苏，而这直接推动了对医疗保健措施的需求。

儘管成长指标积极，但疫苗市场仍面临与疫苗分销复杂物流相关的重大障碍。严格的低温运输储存要求导致营运成本高昂，并造成分销效率低下，尤其是在基础设施薄弱的开发中国家。因此，这些供应链限制构成重大挑战，可能限制基本免疫接种的广泛普及，并阻碍全球旅行疫苗产业的整体扩张。

市场驱动因素

全球国际观光和商务旅行的復苏将是推动市场扩张的关键因素。人员流动增加将直接转化为疫苗接种量的提升。随着航空网络的改善和边境的全面开放，旅客将越来越多地前往地方性疾病肆虐的偏远和热带地区，这些地区存在严重的健康风险，因此接种疫苗至关重要。这种人员流动增加的趋势将确保旅行者健康诊所和製药企业拥有稳定的患者群体，尤其是甲型肝炎、伤寒和黄热病疫苗。国际航空运输协会（IATA）2024年7月发布的《航空旅客市场分析报告》也印证了这一復苏趋势：2024年5月国际旅客需求同比增长14.6%，凸显了跨境旅行的快速復苏对市场需求的支撑作用。

同时，热门旅游目的地新兴和再发感染疾病的日益普及促使旅客在出发前接种疫苗。热带地区虫媒感染疾病的爆发加剧了游客和外籍人士采取预防措施的紧迫性，并推动了新核准疫苗的普及。例如，登革热传播的显着扩大导致对预防方案的需求迅速增长。根据美洲卫生组织（PAHO）2024年3月发布的《登革热流行病学最新情况》，到2024年初，美洲将确诊超过350万例疑似登革热病例，与历史平均水准相比，增幅惊人。这种流行病学情势为疫苗研发商带来了切实的经济效益。巴伐利亚北欧公司（Bavarian Nordic）公布，其2023年全年旅游健康部门的收入为18.77亿丹麦克朗，这表明高感染风险带来了显着的商业性影响。

市场挑战

复杂的物流和严格的低温运输储存要求对全球旅行疫苗市场的成长构成了重大障碍。旅行疫苗属于生物製药，通常需要在整个运输过程中进行精确的温度控制，从冷藏到超低温不等。在基础设施欠发达的地区，维持这种温度连续性不仅在操作上具有挑战性，而且在经济上也负担沉重。由此导致的高昂营运成本和产品劣化风险增加，阻碍了生产商和经销商有效率地进入这些市场。因此，这种物流方面的脆弱性有效地限制了收入潜力，因为该行业正努力确保在最需要的地区提供必要的疫苗。

由于必须透过受限的供应链网路运输大量产品，营运负担进一步加重。运送大量对温度敏感的管瓶的压力加剧了现有分销效率低下的问题。根据联合国儿童基金会2024年年度供应报告，该组织在2024年向99个国家分发了27.87亿剂疫苗。透过脆弱的低温运输处理如此庞大的数量，不可避免地会导致瓶颈和供应中断。这些限制直接限制了市场覆盖范围，并削弱了该行业充分利用全球旅游业復苏带来的医疗保健需求成长的能力。

市场趋势

针对媒介传播疾病的新型疫苗的商业化，正推动市场从研发阶段转向已通过核准的、用于预防被忽视的热带疾病的药物供应阶段。研发人员正推动监管审批流程，并将针对基孔肯雅热等疾病的疫苗推向市场，填补了前往流行地区旅客预防保健方面的空白。这种从开发平臺到商业化的转变，能够即时创造商业性价值，并促进旅行健康产品组合扩展到传统疫苗之外。根据巴伐利亚北欧公司（Bavarian Nordic A/S）于2025年11月发布的“2025年前第一季季度中期财务业绩”，其旅行健康业务的收入增长了23%，达到23.27亿丹麦克朗。这一成长势头得益于该公司基孔肯雅疫苗Vimkunya的商业性化上市。

同时，多价疫苗和结合疫苗製剂的研发正在重塑疫苗接种策略，单一产品即可提供广谱保护。与单价疫苗相比，四价疫苗（可同时针对多种病毒血清型进行免疫）技术简化了接种流程，提高了旅客的依从性，因此，生产商正优先研发此类技术。这项创新透过减轻旅游医疗保健机构的后勤负担，改善了临床疗效并加速了市场渗透。根据武田药品工业株式会社于2025年1月发布的“2024财年第三季度财务业绩”，该公司四价登革热疫苗“Qdenga”上半年销售额达199亿日元，较去年同期增长863%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球旅行疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依成分（单药疫苗与合併疫苗）
  • 依疾病分类（甲型肝炎、百白破疫苗、黄热病、伤寒、B型肝炎、麻疹/腮腺炎、狂犬病、脑膜炎双球菌病、水痘、日本脑炎、其他）
  • 依旅行类型（国内旅行与国际旅行）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美旅行疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲旅行疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区旅行疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲旅行疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲旅行疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球旅行疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GlaxoSmithKline, plc
• Sanofi SA
• Novartis International AG
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Abbott Laboratories, Inc
• F. Hoffmann-La Roche AG
• CSL Limited
• Johnson & Johnson

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Travel Vaccine Market is projected to expand from USD 6.81 Billion in 2025 to USD 11.56 Billion by 2031, achieving a CAGR of 9.22%. Travel vaccines are biological preparations designed to provide acquired immunity against endemic infectious diseases for individuals traveling to specific regions. The market's growth is primarily fueled by the strong recovery of international tourism and stringent government mandates that require immunization for visa approvals. This expansion is further bolstered by rising global disposable incomes, which enable greater cross-border mobility and business travel. UN Tourism data indicates that in 2024, international tourist arrivals recovered to 96 percent of pre-pandemic levels within the first seven months, signaling a robust resurgence in global movement that directly drives the demand for prophylactic healthcare measures.

Despite these favorable growth indicators, the market encounters significant obstacles related to the complex logistics required for vaccine distribution. Stringent cold chain storage necessities impose high operational costs and create distribution inefficiencies, particularly in developing nations that lack robust infrastructure. Consequently, these supply chain constraints constitute a substantial challenge that could limit the widespread accessibility of essential immunizations and hinder the overall expansion of the global travel vaccine sector.

Market Driver

The revival of global international tourism and business travel serves as a major catalyst for market expansion, as heightened mobility directly leads to increased vaccine administration. As air connectivity improves and borders fully reopen, travelers are increasingly visiting exotic and tropical locations where endemic diseases present significant health risks, necessitating prophylactic immunization. This upward trend in mobility secures a sustained patient base for travel medicine clinics and pharmaceutical manufacturers, particularly for vaccines protecting against hepatitis A, typhoid, and yellow fever. Highlighting this recovery, the International Air Transport Association's 'Air Passenger Market Analysis' from July 2024 noted that total international passenger demand increased by 14.6 percent in May 2024 compared to the previous year, underscoring the rapid restoration of cross-border movement that supports market demand.

Simultaneously, the rising prevalence of emerging and re-emerging infectious diseases in popular tourist destinations compels travelers to obtain vaccinations before departure. Outbreaks of vector-borne illnesses in tropical regions have increased the urgency for preventative measures among tourists and business expatriates, driving the adoption of newly approved immunization options. For example, the significant expansion of dengue fever transmission zones has created an acute demand for preventative solutions. The Pan American Health Organization reported in its March 2024 'Epidemiological Update Dengue' that the Americas region saw over 3.5 million suspected dengue cases in early 2024, a staggering rise compared to historical averages. This epidemiological landscape generates tangible financial gains for vaccine developers; Bavarian Nordic reported that its Travel Health segment achieved revenues of DKK 1,877 million for the full year of 2023, reflecting the robust commercial impact of high infection risks.

Market Challenge

Complex logistics and stringent cold chain storage requirements act as a formidable barrier to the growth of the Global Travel Vaccine Market. Travel vaccines are biological products that typically require precise temperature controls, ranging from refrigerated to cryogenic states, throughout their entire transit. in regions with underdeveloped infrastructure, maintaining this thermal continuity is both operationally difficult and financially burdensome. The resulting high operational costs and elevated risks of product spoilage deter manufacturers and distributors from efficiently expanding into these markets. Consequently, this logistical fragility effectively places a ceiling on revenue potential, as the industry struggles to guarantee the reliable availability of essential immunizations in destinations where they are most needed.

This operational strain is further intensified by the immense volume of products that must navigate these often-constrained supply networks. The pressure to transport vast quantities of temperature-sensitive vials amplifies existing distribution inefficiencies. According to UNICEF's Supply Annual Report 2024, the organization managed the international delivery of 2.787 billion vaccine doses to 99 countries in 2024. Processing such a massive volume through fragile cold chains inevitably leads to bottlenecks and supply interruptions. These constraints directly restrict market reach and undermine the industry's capacity to fully capitalize on the heightened demand for prophylactic healthcare driven by the resurgence of global tourism.

Market Trends

The commercialization of novel vaccines for vector-borne diseases is shifting the market from research to the availability of approved prophylactics for neglected tropical illnesses. Developers are navigating regulatory pathways to launch immunizations for diseases like chikungunya, filling the preventative care gap for travelers visiting endemic regions. This transition from pipeline to product generates immediate commercial value and expands the travel health portfolio beyond traditional vaccines. According to Bavarian Nordic A/S, in its November 2025 'Interim Results for the First Nine Months of 2025', Travel Health revenue increased by 23 percent to DKK 2,327 million, a growth trajectory supported by the commercial launch of its chikungunya vaccine, Vimkunya.

Concurrently, the development of multivalent and combination vaccine formulations is reshaping immunization strategies by offering broad-spectrum protection through single-product solutions. Manufacturers are prioritizing tetravalent technologies that induce immunity against multiple virus serotypes simultaneously, simplifying vaccination schedules and enhancing traveler compliance compared to monovalent alternatives. This innovation improves clinical outcomes and drives market uptake by streamlining the logistical burden for travel medicine providers. According to Takeda Pharmaceutical Company Limited's January 2025 'earnings results for the third quarter of fiscal year 2024', the company reported that its tetravalent dengue vaccine, Qdenga, generated 19.9 billion JPY in revenue for the first half of the fiscal year, marking an 863 percent increase.

Key Market Players

• GlaxoSmithKline, plc
• Sanofi S.A.
• Novartis International AG
• Merck KGaA
• Pfizer Inc.
• AstraZeneca Plc
• Abbott Laboratories, Inc
• F. Hoffmann-La Roche AG
• CSL Limited
• Johnson & Johnson

Report Scope

In this report, the Global Travel Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Travel Vaccine Market, By Composition

• Mono Vaccines v/s Combination Vaccines

Travel Vaccine Market, By Disease Indication

• Hepatitis A
• DPT
• Yellow Fever
• Typhoid
• Hepatitis B
• Measles and Mumps
• Rabies
• Meningococcal
• Varicella
• Japanese Encephalitis
• Others

Travel Vaccine Market, By Travel Type

• Domestic v/s International

Travel Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Travel Vaccine Market.

Available Customizations:

Global Travel Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Travel Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Composition (Mono Vaccines v/s Combination Vaccines)
  • 5.2.2. By Disease Indication (Hepatitis A, DPT, Yellow Fever, Typhoid, Hepatitis B, Measles and Mumps, Rabies, Meningococcal, Varicella, Japanese Encephalitis, Others)
  • 5.2.3. By Travel Type (Domestic v/s International)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Travel Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Composition
  • 6.2.2. By Disease Indication
  • 6.2.3. By Travel Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Travel Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Composition
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By Travel Type
  • 6.3.2. Canada Travel Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Composition
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By Travel Type
  • 6.3.3. Mexico Travel Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Composition
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By Travel Type

7. Europe Travel Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Composition
  • 7.2.2. By Disease Indication
  • 7.2.3. By Travel Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Travel Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Composition
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Travel Type
  • 7.3.2. France Travel Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Composition
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Travel Type
  • 7.3.3. United Kingdom Travel Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Composition
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Travel Type
  • 7.3.4. Italy Travel Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Composition
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By Travel Type
  • 7.3.5. Spain Travel Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Composition
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By Travel Type

8. Asia Pacific Travel Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Composition
  • 8.2.2. By Disease Indication
  • 8.2.3. By Travel Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Travel Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Composition
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Travel Type
  • 8.3.2. India Travel Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Composition
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Travel Type
  • 8.3.3. Japan Travel Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Composition
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Travel Type
  • 8.3.4. South Korea Travel Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Composition
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Travel Type
  • 8.3.5. Australia Travel Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Composition
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Travel Type

9. Middle East & Africa Travel Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Composition
  • 9.2.2. By Disease Indication
  • 9.2.3. By Travel Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Travel Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Composition
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Travel Type
  • 9.3.2. UAE Travel Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Composition
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Travel Type
  • 9.3.3. South Africa Travel Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Composition
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Travel Type

10. South America Travel Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Composition
  • 10.2.2. By Disease Indication
  • 10.2.3. By Travel Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Travel Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Composition
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Travel Type
  • 10.3.2. Colombia Travel Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Composition
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Travel Type
  • 10.3.3. Argentina Travel Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Composition
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Travel Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Travel Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline, plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Novartis International AG
• 15.4. Merck KGaA
• 15.5. Pfizer Inc.
• 15.6. AstraZeneca Plc
• 15.7. Abbott Laboratories, Inc
• 15.8. F. Hoffmann-La Roche AG
• 15.9. CSL Limited
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer